Introducing Viatris: Launching a New Era in Global Health with $335M Empowerment

We are excited to announce a major milestone in our journey as Viatris—the result of a powerful combination with Upjohn, a legacy division of Pfizer.

In a landmark funding announcement, we are proud to share that we have raised $335,000,000, a significant investment that underpins our renewed commitment to global health.

This substantial funding brings us even closer to our mission of empowering people worldwide to live healthier, more fulfilling lives at every stage.

As Viatris, we are not only the legacy of two dynamic leaders in healthcare, but we are also a beacon of innovation and accessibility in pharmaceuticals.

The fresh capital will be strategically allocated to enhance our research and development pipeline, support the advancement of both new and existing therapies, and expand our global reach into underserved markets.

We firmly believe that these investments will help us tackle some of the most pressing healthcare challenges of our time—from infectious diseases to chronic conditions—ensuring that vital medicines become accessible to patients everywhere.

Furthermore, the funding will enable us to further integrate our global operations, streamline our processes, and drive operational efficiencies that ultimately benefit both our healthcare partners and the communities we serve.

This announcement marks not just a financial success, but a meaningful step forward in our evolution as a company that embodies experience, innovation, and an unwavering commitment to public health.

Follow along on our new journey at http://www.linkedin.com/company/viatris and join us as we transform the landscape of global healthcare for the better.